Healthdirect Free Australian health advice you can count on.

Medical problem? Call 1800 022 222. If you need urgent medical help, call triple zero immediately

healthdirect Australia is a free service where you can talk to a nurse or doctor who can help you know what to do.

beginning of content

Brand name: Saxenda

Saxenda is a medicine containing the active ingredient(s) liraglutide. On this page you will find out more about Saxenda, including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS)

You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional. healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.

Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions.

Active ingredient in this medicine: liraglutide

Information for medicine and pack size:
Saxenda 6 mg/mL injection solution, 3 x 3 mL injection devices

Consumer Medicine Information leaflet:

This leaflet may also be found inside the medicine package. It contains information on side effects, age restrictions and other useful data.

Read leaflet

What this medicine is for

SAXENDA is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial Body Mass Index (BMI) of greater than or equal to 30 kg/m2 (obese) or greater than or equal to 27 kg/m2 to less than 30 kg/m2 (overweight) in the presence of at least one weight related comorbidity, such as dysglycaemia (pre-diabetes and type 2 diabetes mellitus), hypertension, dyslipidaemia, or obstructive sleep apnoea.,Treatment with SAXENDA should be discontinued after 12 weeks on the 3.0 mg/day dose if a patient has not lost at least 5% of their initial body weight.,Long term use should be informed by the following: Long term safety data are limited. Adverse reactions that are uncommon (frequency < 1/100) and/or are associated with prolonged use (>12 months) might not have been identified in the clinical development program [refer CLINICAL TRIALS]. Long term efficacy data are limited. The treatment effect has only been documented for 1 year [refer CLINICAL TRIALS].

Table of characteristics
Table of characteristics
Active ingredient
Visual appearance Clear, colourless solution
Dosage Form Injection, solution
Route of administration Subcutaneous
Medicine schedule
1 x 3mL Pre-filled pen - Fill volume - 3mL with an overfill to ensure an extractable amount of at least 3mL: Prescription Only Medicine, or Prescription Animal Remedy
3 x 3mL Pre-filled pen - Fill volume - 3mL with an overfill to ensure an extractable amount of at least 3mL: Prescription Only Medicine, or Prescription Animal Remedy
5 x 3mL Pre-filled pen - Fill volume - 3mL with an overfill to ensure an extractable amount of at least 3mL: Prescription Only Medicine, or Prescription Animal Remedy

There is one type of pack available.

Pack type 1
Pack type 1
Type Cartridge
Storage temperature Store at 2 to 8 degrees Celsius
Storage conditions Protect from Light,Do not Freeze,Refrigerate
Life time 30 Months
We were unable to verify that this medicine is available on the PBS (Pharmaceutical Benefits Scheme). Please consult your pharmacist if you need further information

The PBS provides a list of government subsidised medicines available to be dispensed to patients. Further information can be found on the Pharmaceutical Benefits Scheme website.

Go to PBS site

Is this medication banned in sport?

Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.

Go to ASADA site

The information displayed on this page is authored by Healthdirect Australia, or obtained from trusted sources.

Need more information?

These trusted information partners have more on this topic.

Healthdirect 24hr 7 days a week hotline

24 hour health advice and information you can count on

1800 022 222

Government Accredited with over 140 information partners

We are a government-funded service, providing quality, approved health information

Australian Government, health department logo ACT Government logo New South Wales government, health department logo Northen Territory Government logo Government of South Australia, health department logo Tasmanian government logo Government of Western Australia, health department logo